CymaBay Pipeline

Home / Pipeline

Overview

With a long history of drug discovery and development, CymaBay delivers value to all stakeholders through a deep understanding of the underlying mechanisms of inflammation and fibrosis, unique targets that play a role in their progression, and innovative therapies for liver and other chronic diseases with high unmet medical need. CymaBay’s lead product, Seladelpar, is a first-in-class oral, selective PPARδ agonist that has been shown to regulate critical metabolic and liver disease pathways in indications with high unmet medical need. Seladelpar has received Breakthrough Therapy Designation (FDA) and PRIME status (EMEA); Orphan Drug Designation in U.S. and Europe for the treatment of patients with primary biliary cholangitis (PBC).


Additionally, we have a drug candidate in early development that features a unique mechanism of action with potential to treat other chronic diseases.

  Pre-Clinical Phase 1 Phase 2 Phase 3
Internal Programs
Seladelpar

(PPARδ agonist)

Primary Biliary Cholangitis
Seladelpar
Non-Alcoholic Steatohepatitis
Seladelpar
Primary Sclerosing Cholangitis
MBX-2982

(GPR 119 agonist)

Diabetic Hypoglycemia